Phenobarbital/lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy

Annals of Pharmacotherapy

Volumn 44, Issue 12, 2010, Pages 2031-2034

  Siniscalchi, Antonio ^a   Gallelli, Luca ^b,c   Calabrò, Giuseppina ^b   Tolotta, Grazia Angela ^b,c   De Sarro, Giovambattista ^b,c  

^a ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c Mater Domini University Hospital   (Italy)

Author keywords

Drug drug interaction; Lamotrigine; Leukopenia; Phenobarbital; Thrombocytopenia

Indexed keywords

ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL;

ADULT; ANAMNESIS; ARTICLE; BLOOD DYSCRASIA; BLOOD EXAMINATION; CASE REPORT; CLINICAL EXAMINATION; COMPLEX PARTIAL SEIZURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EPILEPSY; FAMILY HISTORY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOPENIA; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANTICONVULSANTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; LEUKOPENIA; PHENOBARBITAL; THROMBOCYTOPENIA; TRIAZINES;

EID: 78649955813     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P335     Document Type: Article

References (18)

1. Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Epilepsia 1991;32:S74-9.
2. O'Connor CR, Schraeder PL, Kurland AH, O'Connor WH. Evaluation of the mechanisms of antiepileptic drug-related chronic leukopenia. Epilepsia 1994;35:149-54.
3. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004;45:1141-9.
4. Mackay FJ, Wilton LV, Pearce GL, Freemanatle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997;38:881-6.
5. Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. BJM 1995;310:504.
6. de Camargo OA, Bode H. Agranulocytosis associated with lamotrigine. BJM 1999;318:1179.
7. Ural AU, Avcu F, Gokcil Z, Nevruz O, Cetin T. Leucopenia and thrombocytopenia possibly associated with lamotrigine use in a patient. Epileptic Disord 2005;7:33-5. (Pubitemid 40342342)
8. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-85. (Pubitemid 34297175)
9. Johannessen Landmerk C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10:119-40.
10. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423
11. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501. (Pubitemid 30021105)
12. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, Park BK. Metabolism of lamotrigine to reactive arene oxide intermediate. Chem Res Toxicol 2000;13:1075-81.
13. Bottinger Y, Svenssson Jo, Stahle L. Lamotrigine drug interactions in a TDM material. Ther Drug Monit 1999;21:171-4. (Pubitemid 29168894)
14. May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996;18:523-31.
15. Deckers CL, Hekster YA, Keyser A, Meinardi H, Renier WO. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997;38:570-5.
16. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998;39:183-7.
17. Hacquard M, Richard S, Lacour JC, Lecompte T, Vespignani H. Levetiracetam-induced platelet dysfunction. Epilepsy Res 2009;86:94-6.
18. Gallerani M, Mari E, Boari B, Carletti R, Marra A, Cavallo M. Pancytopenia associated with levetiracetam treatment. Clin Drug Investig 2009;29:747-51. DOI 10.2165/11319450-000000000-00000